Cardiovascular risk in patients with renal disease: treating the risk or treating the risk factor?
Rabelink
Ton J
TJ
University Medical Center Utrecht, Internal Medicine, Room G 02.228, PO Box 85500, 3508 GA Utrecht, The Netherlands. t.rabelink@azu.nl
D000328:Adult; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D019587:Dietary Supplements; D005492:Folic Acid / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications / Q000401:mortality*; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012306:Risk; D012307:Risk Factors
D000959:Antihypertensive Agents; D000960:Hypolipidemic Agents; D010975:Platelet Aggregation Inhibitors; D005492:Folic Acid; D001241:Aspirin